Effects of clinically used antioxidants in experimental pneumococcal meningitis

J Infect Dis. 2000 Jul;182(1):347-50. doi: 10.1086/315658. Epub 2000 Jul 6.

Abstract

Reactive oxygen intermediates mediate brain injury in bacterial meningitis. Several antioxidant drugs are clinically available, including N-acetylcysteine (NAC), deferoxamine (DFO), and trylizad-mesylate (TLM). The present study evaluated whether these antioxidants are beneficial in a model of pneumococcal meningitis. Eleven-day-old rats were infected intracisternally with Streptococcus pneumoniae and randomized to intraperitoneal treatment every 8 h with NAC (200 mg/kg), DFO (100 mg/kg), TLM (10 mg/kg), or saline (250 microL). TLM-treated animals showed a significantly reduced mortality compared with controls (P<.03). Meningitis led to extensive cortical injury at 22+/-2.2 h after infection (median, 14. 6% of cortex; range, 0-61.1%). Injury was significantly (P<.01) reduced to 1.1% (range, 0-34.6%) by NAC, to 2.3% (range, 0-19.6%) by DFO, and to 0.2% (range, 0-36.9%) by TLM (the difference was not significant among the 3 groups). None of the drugs reduced hippocampal injury. Thus, several clinically used antioxidants reduced cortical injury in experimental pneumococcal meningitis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acetylcysteine / therapeutic use
  • Animals
  • Antioxidants / therapeutic use*
  • Deferoxamine / therapeutic use
  • Disease Models, Animal
  • Meningitis, Pneumococcal / drug therapy*
  • Meningitis, Pneumococcal / metabolism
  • Meningitis, Pneumococcal / pathology
  • Neurons / drug effects
  • Neurons / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antioxidants
  • Tumor Necrosis Factor-alpha
  • Deferoxamine
  • Acetylcysteine